Circulating peroxiredoxin 4 and type 2 diabetes risk: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study

Diabetologia

Volumn 57, Issue 9, 2014, Pages 1842-1849

  Abbasi, Ali ^a,b   Corpeleijn, Eva ^a   Gansevoort, Ron T ^a   Gans, Rijk O B ^a   Struck, Joachim ^c   Schulte, Janin ^d   Hillege, Hans L ^a   Van Der Harst, Pim ^a,e   Stolk, Ronald P ^a   Navis, Gerjan ^a   Bakker, Stephan J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ADRENOMED AG   (Germany)

^d THERMO FISHER SCIENTIFIC   (Germany)

^e ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Epidemiology; Peroxiredoxin 4; Risk prediction; Sex difference; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXIREDOXIN 4; PROCALCITONIN; TRIACYLGLYCEROL; PEROXIREDOXIN; CHOLESTEROL; INSULIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; C STATISTIC; ENZYME BLOOD LEVEL; FAMILY HISTORY; FEMALE; FOLLOW UP; GENDER; GENE LOCATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTEGRATED DISCRIMINATION IMPROVEMENT; MAJOR CLINICAL STUDY; MALE; NET RECLASSIFICATION IMPROVEMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SMOKING; WAIST CIRCUMFERENCE; X CHROMOSOME; ADVERSE EFFECTS; BLOOD; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; PHYSIOLOGY; CONTROLLED STUDY; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; PROTEIN BLOOD LEVEL;

ADULT; AGE FACTORS; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PEROXIREDOXINS; RISK FACTORS; SEX FACTORS; SMOKING; WAIST CIRCUMFERENCE;

EID: 84905575037     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3278-9     Document Type: Article

References (43)

1. Seshasai SR, Kaptoge S, Thompson A, et al. (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829-841
2. Danaei G, Finucane MM, Lu Y, et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378:31-40
3. Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115:1111-1119
4. Giustarini D, Dalle-Donne I, Tsikas D, Rossi R (2009) Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Crit Rev Clin Lab Sci 46:241-281
5. Matsushita K, Williams EK, Mongraw-Chaffin ML, et al. (2012) The association of plasma lactate with incident cardiovascular outcomes: the ARIC study. Am J Epidemiol 178:401-409
6. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A (2006) Biomarkers of oxidative damage in human disease. Clin Chem 52:601-623
7. Strobel NA, Fassett RG, Marsh SA, Coombes JS (2011) Oxidative stress biomarkers as predictors of cardiovascular disease. Int J Cardiol 147:191-201
8. Melander O, Newton-Cheh C, Almgren P, et al. (2009) Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302:49-57
9. Nabeshima A, Yamada S, Guo X, et al. (2013) Peroxiredoxin 4 protects against nonalcoholic steatohepatitis and type 2 diabetes in a nongenetic mouse model. Antioxid Redox Signal 19:1983-1998
10. Barcelo-Batllori S, Corominola H, Claret M, Canals I, Guinovart J, Gomis R (2005) Target identification of the novel antiobesity agent tungstate in adipose tissue from obese rats. Proteomics 5:4927-4935
11. Ding Y, Yamada S, Wang KY, et al. (2010) Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice. Antioxid Redox Signal 13:1477-1490
12. Wei Q, Jiang H, Xiao Z, et al. (2011) Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling. Proc Natl Acad Sci U S A 108:7004-7009
13. Okado-Matsumoto A, Matsumoto A, Fujii J, Taniguchi N (2000) Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions. J Biochem 127:493-501
14. Schulte J, Struck J, Bergmann A, Kohrle J (2010) Immunoluminometric assay for quantification of peroxiredoxin 4 in human serum. Clin Chim Acta 411:1258-1263
15. Abbasi A, Corpeleijn E, Postmus D, et al. (2012) Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality. J Am Heart Assoc 1:e002956
16. Schulte J, Struck J, Kohrle J, Muller B (2011) Circulating levels of peroxiredoxin 4 as a novel biomarker of oxidative stress in patients with sepsis. Shock 35:460-465
17. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT (2008) Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 168:897-905
18. Mahmoodi BK, Gansevoort RT, Veeger NJ, et al. (2009) Microalbuminuria and risk of venous thromboembolism. JAMA 301:1790-1797
19. Abbasi A, Corpeleijn E, Postmus D, et al. (2010) Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome. J Clin Endocrinol Metab 95:E26-E31
20. Abbasi A, Corpeleijn E, Postmus D, et al. (2011) Plasma procalcitonin and risk of type 2 diabetes in the general population. Diabetologia 54:2463-2465
21. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T (2011) Risk models and scores for type 2 diabetes: systematic review. BMJ 343:d7163
22. Abbasi A, Peelen LM, Corpeleijn E, et al. (2012) Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. BMJ 345:e5900
23. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R (2003) Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 26:3320-3325
24. Hivert MF, Sullivan LM, Shrader P, et al. (2011) Insulin resistance influences the association of adiponectin levels with diabetes incidence in two population-based cohorts: the Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study and the Framingham Offspring Study. Diabetologia 54:1019-1024
25. Fleiss JL (1986) Analysis of data from multiclinic trials. Control Clin Trials 7:267-275
26. Balkau B, Lange C, Fezeu L, et al. (2008) Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 31:2056-2061
27. Paynter NP, Mazer NA, Pradhan AD, Gaziano JM, Ridker PM, Cook NR (2011) Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent. Arch Intern Med 171:1712-1718
28. Pencina MJ, D'Agostino RB Sr, Steyerberg EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30:11-21
29. Knuiman MW, Divitini ML, Buzas JS, Fitzgerald PE (1998) Adjustment for regression dilution in epidemiological regression analyses. Ann Epidemiol 8:56-63
30. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr (2007) Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 167:1068-1074
31. El Eter E, Al Masri A, Habib S, et al. (2014) Novel links among peroxiredoxins, endothelial dysfunction, and severity of atherosclerosis in type 2 diabetic patients with peripheral atherosclerotic disease. Cell Stress Chaperones 19:173-181
32. Dreja T, Jovanovic Z, Rasche A, et al. (2010) Diet-induced gene expression of isolated pancreatic islets from a polygenic mouse model of the metabolic syndrome. Diabetologia 53:309-320
33. Houstis N, Rosen ED, Lander ES (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440:944-948
34. Wood ZA, Schroder E, Robin Harris J, Poole LB (2003) Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28:32-40
35. Nickel CH, Ruedinger J, Misch F, et al. (2011) Copeptin and peroxiredoxin-4 independently predict mortality in patients with nonspecific complaints presenting to the emergency department. Acad Emerg Med 18:851-859
36. Hillege HL, Fidler V, Diercks GF, et al. (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777-1782
37. Wormser D, Kaptoge S, Di Angelantonio E, et al. (2011) Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 377:1085-1095
38. Schulte J (2011) Peroxiredoxin 4: a multifunctional biomarker worthy of further exploration. BMC Med 9:137
39. Jin DY, Chae HZ, Rhee SG, Jeang KT (1997) Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation. J Biol Chem 272:30952-30961
40. Wong CM, Chun AC, Kok KH, et al. (2000) Characterization of human and mouse peroxiredoxin IV: evidence for inhibition by Prx-IV of epidermal growth factor- and p53-induced reactive oxygen species. Antioxid Redox Signal 2:507-518
41. Giguere P, Turcotte ME, Hamelin E, et al. (2007) Peroxiredoxin-4 interacts with and regulates the thromboxane A(2) receptor. FEBS Lett 581:3863-3868
42. Bertolotti M, Yim SH, Garcia-Manteiga JM, et al. (2010) B- to plasma-cell terminal differentiation entails oxidative stress and profound reshaping of the antioxidant responses. Antioxid Redox Signal 13:1133-1144
43. Pergola PE, Raskin P, Toto RD, et al. (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365:327-336